^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MP0533

    i
    Other names: MP0533
    Associations

    News

    Trials
    Company:
    Molecular Partners
    Drug class:
    CD3 agonist, CD123 inhibitor, T-cell stimulant, CD70 inhibitor, CD33 modulator
    Related drugs:
    Associations

    News

    Trials
    7ms
    The CD33xCD123xCD70 Multispecific CD3-Engaging DARPin MP0533 Induces Selective T Cell-Mediated Killing of AML Leukemic Stem Cells. (PubMed, Cancer Immunol Res)
    These studies show that the multispecific-targeting strategy used with MP0533 holds promise for improved selectivity towards LSCs and efficacy against clonal heterogeneity, potentially bringing a new therapeutic option to this group of patients with high unmet need. MP0533 is currently being evaluated in a dose-escalation phase 1 study in patients with relapsed or refractory AML (NCT05673057).
    Journal
    |
    CD123 (Interleukin 3 Receptor Subunit Alpha) • CD33 (CD33 Molecule) • CD70 (CD70 Molecule) • IL3RA (Interleukin 3 Receptor Subunit Alpha)
    |
    MP0533
    1year
    MP0533, a CD3-Engaging Darpin Targeting CD33, CD123, and CD70 in Patients with Relapsed/Refractory AML or MDS/AML: Preliminary Results of a Phase 1/2a Study (ASH 2023)
    The results of this ongoing phase 1/2a study indicated an acceptable safety profile of MP0533 monotherapy in 5 patients up to DR 3 with weekly infusions. Preliminary response data are encouraging, with one response observed in 1 of 2 patients evaluable for response in DR 3 to date.
    Clinical • P1/2 data • IO biomarker
    |
    TP53 (Tumor protein P53) • CD123 (Interleukin 3 Receptor Subunit Alpha) • CD33 (CD33 Molecule) • CD70 (CD70 Molecule) • IL3RA (Interleukin 3 Receptor Subunit Alpha)
    |
    TP53 mutation
    |
    MP0533
    over2years
    MP0533, A NEW MULTISPECIFIC DARPIN CD3 ENGAGER TARGETING THREE TUMOR ASSOCIATED ANTIGENS, INDUCES SPECIFIC T-CELL ACTIVATION AND AML TUMOR KILLING IN VIVO (EHA 2022)
    However, MP0533 didn't induce significant cytokine release, including at the highest tested dose, in mice serum four hours after the first injection. Conclusion We were able to generate a multi-specific CD3 engaging DARPin molecule with tailored affinities towards different TAAs showing significant efficacy in vivo that induced T cell activation without significant cytokine/chemokine release.
    Preclinical
    |
    CD8 (cluster of differentiation 8) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD123 (Interleukin 3 Receptor Subunit Alpha) • IL2RA (Interleukin 2 receptor, alpha) • CD33 (CD33 Molecule) • CD70 (CD70 Molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CD69 (CD69 Molecule)
    |
    MP0533